Gene therapy bad news #1: From Pharmalittle newsletter of @statnews.com: "Bluebird Bio announced it would sell itself & its portfolio of gene therapies to the investment firms Carlyle & SK Capital for less than $30 m, in a deal that lets the beleaguered biotech avoid bankruptcy, STAT says. The sale
Comments
Amazing cures, going out of business. We need a better model! Maybe the increasingly bad news will lead to openness on getting to one. Wish I had hopes for useful US federal action. Between/Medicare & Medicaid it may be essential, but I fear extreme Admin myopia (at best).